SLC5A2 and type 2 diabetes mellitus: In Europe, four different types of SGLT2 inhibitors have been approved for clinical use in T2DM patients who are at cardiovascular risk: dapagliflozin (Forxiga; Astra Zeneca, Cambridge, UK), empagliflozin (Jardiance; Boeringher Ingelheim, Ingelheim am Rhein, Germany), canagliflozin (Invokana; Janssen Research & Development, LLC, Raritan, NJ, USA), and ertugliflozin (Steglatro; Pfizer, New York, NY, USA) [51,52,53,54].